유형균 교수
주요 경력 | 분당차병원 임상약리학과 임상조교수
학위 | 서울대학교 박사
Email | hgyoo0317@cha.ac.kr
연구 기술 분야 | 연구 기술 분야: 신약 개발 초기 임상 시험, 맞춤 약물 요법, 약물 유전체학
Yoo, H., Ji, S. C., Cho, J. Y., Kim, S. H., Yoon, J. G., Lee, M. G., ... & Oh, J. (2021). A pilot study to investigate the utility of NAT2 genotype-guided isoniazid monotherapy regimens in NAT2 slow acetylators. Pharmacogenetics and Genomics, 31(3), 68-73.
Huh, K. Y., Kim, E., Lee, S., Yoo, H., Yoon, S., Yu, K. S., & Chung, J. Y. (2021). Current bioequivalence study designs in South Korea: a comprehensive analysis of bioequivalence study reports between 2013 and 2019. Frontiers in pharmacology, 12.
Sa, S., Lee, C. W., Shim, S. R., Yoo, H., Choi, J., Kim, J. H., ... & Han, H. W. (2022). The Safety of mRNA-1273, BNT162b2 and JNJ-78436735 COVID-19 Vaccines: Safety Monitoring for Adverse Events Using Real-World Data. Vaccines, 10(2), 320.
Lee, H. A., Ju Moon, S., Yoo, H., Kyung Kim, M., Bok Jang, S., Lee, S., ... & Lee, H. (2021). YH12852, a potent and selective receptor agonist of 5‐hydroxytryptamine, increased gastrointestinal motility in healthy volunteers and patients with functional constipation. Clinical and translational science, 14(2), 625-634.
Hwang, I., Kim, Y., Yoo, H., Jang, I. J., Yu, K. S., & Lee, S. (2020). Pharmacokinetic/Pharmacodynamic Interaction Between Evogliptin and Pioglitazone in Healthy Male Subjects. Drug Design, Development and Therapy, 14, 4493.
Yoo, H., Kim, Y., Jang, I. J., Yu, K. S., & Lee, S. (2020). Pharmacokinetic/Pharmacodynamic Interactions Between Evogliptin and Glimepiride in Healthy Male Subjects. Drug Design, Development and Therapy, 14, 5179.
Yang, E., Yoo, H., Jang, I. J., Yu, K. S., & Lee, S. (2021). Pharmacokinetic and Pharmacodynamic Comparison of Two Formulations of a Fixed-Dose Combination of Gemigliptin/Rosuvastatin 50/20 mg: A Randomized, Open-Label, Single-Dose, Two-Way Crossover Study. Drug Design, Development and Therapy, 15, 651.
Yoo, H., Lee, S. W., Yoon, D. Y., Yoon, S. H., Cho, J. Y., Yu, K. S., ... & Lee, S. (2021). Pharmacokinetics and Safety of Extended-release Ranolazine in Korean and White Healthy Subjects. Clinical Therapeutics, 43(3), 526-534.